 | • レポートコード：MRC23Q35996 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、83ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の脂肪肝治療薬市場について調査・分析し、世界の脂肪肝治療薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（ALD、NAFLD）、用途別セグメント分析（病院、クリニック）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Pfizer、Gilead Sciences、Astra Zenca、Immuron、Novartis、Takeda、Allergan、Intercept Pharmaceuticals、Conatusなどが含まれています。 世界の脂肪肝治療薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、脂肪肝治療薬市場規模を推定する際に考慮しました。本レポートは、脂肪肝治療薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、脂肪肝治療薬に関するビジネス上の意思決定に役立てることを目的としています。 ・脂肪肝治療薬市場の概要 - 脂肪肝治療薬のタイプ別セグメント - 世界の脂肪肝治療薬市場規模：タイプ別分析（ALD、NAFLD） - 脂肪肝治療薬の用途別セグメント - 世界の脂肪肝治療薬市場規模：用途別分析（病院、クリニック） - 世界の脂肪肝治療薬市場規模予測（2018年-2029年） ・脂肪肝治療薬市場の成長トレンド - 脂肪肝治療薬の地域別市場規模（2018年-2029年） - 脂肪肝治療薬市場ダイナミクス - 脂肪肝治療薬の業界動向 - 脂肪肝治療薬市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：ALD、NAFLD - 世界の脂肪肝治療薬のタイプ別市場規模（2018年-2023年） - 世界の脂肪肝治療薬のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、クリニック - 世界の脂肪肝治療薬の用途別市場規模（2018年-2023年） - 世界の脂肪肝治療薬の用途別市場規模（2024年-2029年） ・脂肪肝治療薬の地域別市場規模 - 北米の脂肪肝治療薬市場規模（2018年-2029年） - アメリカの脂肪肝治療薬市場規模（2018年-2029年） - ヨーロッパの脂肪肝治療薬市場規模（2018年-2029年） - アジア太平洋の脂肪肝治療薬市場規模（2018年-2029年） - 中国の脂肪肝治療薬市場規模（2018年-2029年） - 日本の脂肪肝治療薬市場規模（2018年-2029年） - 韓国の脂肪肝治療薬市場規模（2018年-2029年） - インドの脂肪肝治療薬市場規模（2018年-2029年） - オーストラリアの脂肪肝治療薬市場規模（2018年-2029年） - 中南米の脂肪肝治療薬市場規模（2018年-2029年） - 中東・アフリカの脂肪肝治療薬市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Pfizer、Gilead Sciences、Astra Zenca、Immuron、Novartis、Takeda、Allergan、Intercept Pharmaceuticals、Conatus ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Fatty Liver Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Fatty Liver Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Fatty Liver Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Fatty Liver Drugs in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Fatty Liver Drugs include Pfizer, Gilead Sciences, Astra Zenca, Immuron, Novartis, Takeda, Allergan, Intercept Pharmaceuticals and Conatus, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Fatty Liver Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fatty Liver Drugs.
The Fatty Liver Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Fatty Liver Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Fatty Liver Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer
Gilead Sciences
Astra Zenca
Immuron
Novartis
Takeda
Allergan
Intercept Pharmaceuticals
Conatus
Segment by Type
ALD
NAFLD
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Fatty Liver Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Fatty Liver Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 ALD
1.2.3 NAFLD
1.3 Market by Application
1.3.1 Global Fatty Liver Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Fatty Liver Drugs Market Perspective (2018-2029)
2.2 Fatty Liver Drugs Growth Trends by Region
2.2.1 Global Fatty Liver Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Fatty Liver Drugs Historic Market Size by Region (2018-2023)
2.2.3 Fatty Liver Drugs Forecasted Market Size by Region (2024-2029)
2.3 Fatty Liver Drugs Market Dynamics
2.3.1 Fatty Liver Drugs Industry Trends
2.3.2 Fatty Liver Drugs Market Drivers
2.3.3 Fatty Liver Drugs Market Challenges
2.3.4 Fatty Liver Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Fatty Liver Drugs Players by Revenue
3.1.1 Global Top Fatty Liver Drugs Players by Revenue (2018-2023)
3.1.2 Global Fatty Liver Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Fatty Liver Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Fatty Liver Drugs Revenue
3.4 Global Fatty Liver Drugs Market Concentration Ratio
3.4.1 Global Fatty Liver Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Fatty Liver Drugs Revenue in 2022
3.5 Fatty Liver Drugs Key Players Head office and Area Served
3.6 Key Players Fatty Liver Drugs Product Solution and Service
3.7 Date of Enter into Fatty Liver Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Fatty Liver Drugs Breakdown Data by Type
4.1 Global Fatty Liver Drugs Historic Market Size by Type (2018-2023)
4.2 Global Fatty Liver Drugs Forecasted Market Size by Type (2024-2029)
5 Fatty Liver Drugs Breakdown Data by Application
5.1 Global Fatty Liver Drugs Historic Market Size by Application (2018-2023)
5.2 Global Fatty Liver Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Fatty Liver Drugs Market Size (2018-2029)
6.2 North America Fatty Liver Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Fatty Liver Drugs Market Size by Country (2018-2023)
6.4 North America Fatty Liver Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Fatty Liver Drugs Market Size (2018-2029)
7.2 Europe Fatty Liver Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Fatty Liver Drugs Market Size by Country (2018-2023)
7.4 Europe Fatty Liver Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Fatty Liver Drugs Market Size (2018-2029)
8.2 Asia-Pacific Fatty Liver Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Fatty Liver Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Fatty Liver Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Fatty Liver Drugs Market Size (2018-2029)
9.2 Latin America Fatty Liver Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Fatty Liver Drugs Market Size by Country (2018-2023)
9.4 Latin America Fatty Liver Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Fatty Liver Drugs Market Size (2018-2029)
10.2 Middle East & Africa Fatty Liver Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Fatty Liver Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Fatty Liver Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Fatty Liver Drugs Introduction
11.1.4 Pfizer Revenue in Fatty Liver Drugs Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Detail
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences Fatty Liver Drugs Introduction
11.2.4 Gilead Sciences Revenue in Fatty Liver Drugs Business (2018-2023)
11.2.5 Gilead Sciences Recent Development
11.3 Astra Zenca
11.3.1 Astra Zenca Company Detail
11.3.2 Astra Zenca Business Overview
11.3.3 Astra Zenca Fatty Liver Drugs Introduction
11.3.4 Astra Zenca Revenue in Fatty Liver Drugs Business (2018-2023)
11.3.5 Astra Zenca Recent Development
11.4 Immuron
11.4.1 Immuron Company Detail
11.4.2 Immuron Business Overview
11.4.3 Immuron Fatty Liver Drugs Introduction
11.4.4 Immuron Revenue in Fatty Liver Drugs Business (2018-2023)
11.4.5 Immuron Recent Development
11.5 Novartis
11.5.1 Novartis Company Detail
11.5.2 Novartis Business Overview
11.5.3 Novartis Fatty Liver Drugs Introduction
11.5.4 Novartis Revenue in Fatty Liver Drugs Business (2018-2023)
11.5.5 Novartis Recent Development
11.6 Takeda
11.6.1 Takeda Company Detail
11.6.2 Takeda Business Overview
11.6.3 Takeda Fatty Liver Drugs Introduction
11.6.4 Takeda Revenue in Fatty Liver Drugs Business (2018-2023)
11.6.5 Takeda Recent Development
11.7 Allergan
11.7.1 Allergan Company Detail
11.7.2 Allergan Business Overview
11.7.3 Allergan Fatty Liver Drugs Introduction
11.7.4 Allergan Revenue in Fatty Liver Drugs Business (2018-2023)
11.7.5 Allergan Recent Development
11.8 Intercept Pharmaceuticals
11.8.1 Intercept Pharmaceuticals Company Detail
11.8.2 Intercept Pharmaceuticals Business Overview
11.8.3 Intercept Pharmaceuticals Fatty Liver Drugs Introduction
11.8.4 Intercept Pharmaceuticals Revenue in Fatty Liver Drugs Business (2018-2023)
11.8.5 Intercept Pharmaceuticals Recent Development
11.9 Conatus
11.9.1 Conatus Company Detail
11.9.2 Conatus Business Overview
11.9.3 Conatus Fatty Liver Drugs Introduction
11.9.4 Conatus Revenue in Fatty Liver Drugs Business (2018-2023)
11.9.5 Conatus Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details